Internal Medicine, Pulmonary Disease · Sacramento, CA
NPI
1811972920
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2315 Stockton Blvd
Sacramento, CA, 95817
Phone (916) 734-3564
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,328
130 services
Medicare patients, 2024
79
Average age 70
Drug cost, 2024
$1.7M
1,319 prescriptions
Company payments, 2025
$508K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samuel Louie was code 99214 (office e&m - established), 53 times for 44 patients. In total Samuel Louie billed 130 services in 9 codes, and Medicare paid $9,328.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-10-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 53 | 44 | $71.28 | $3,778 |
| 99215 Office E&M - Established | Office | 26 | 21 | $99.42 | $2,585 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 18 | 18 | $13.40 | $241 |
| 99205 Office E&M - New | Office | 13 | 13 | $139.90 | $1,819 |
By year: 2022 $12K for 185 services; 2023 $9,151 for 109 services; 2024 $9,328 for 130 services.
Medicare prescription drug claims, 2024
In 2024, the drug Samuel Louie prescribed most often to Medicare patients was Dupixent Pen (Dupilumab), with 144 prescriptions and refills. In total Samuel Louie wrote 1,319 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | 144 | 147 | 17 | $530K |
| Nucala Mepolizumab | 111 | 111 | 12 | $406K |
| Prednisone Generic | 90 | 98 | 44 | $217 |
| Montelukast Sodium Generic | 72 | 170 | 20 | $725 |
| Breo Ellipta Fluticasone/Vilanterol | 69 | 93 | 13 | $36K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 60 | 69 | 19 | $2,398 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 59 | 75 | Under 11 | $46K |
| Epinephrine Generic | 58 | 58 | 46 | $11K |
| Fasenra Pen Benralizumab | 55 | 97 | Under 11 | $337K |
| Azithromycin Generic | 49 | 49 | 33 | $200 |
| Spiriva Respimat Tiotropium Bromide | 39 | 47 | Under 11 | $24K |
| Roflumilast Generic | 36 | 36 | Under 11 | $1,214 |
| Tezspire Tezepelumab-Ekko | 35 | 35 | Under 11 | $153K |
| Ipratropium Bromide Generic | 30 | 41 | Under 11 | $1,408 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 26 | 34 | Under 11 | $21K |
Brand drugs: 802 claims; generic drugs: 517 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Samuel Louie $508K ($508K in general payments such as food, travel and fees) from 8 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $141K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.